The case for an outright sale
Merck KGaA agreed to acquire Silence Therapeutics in a transaction reported at about $1.3 billion, all cash. For a company and its shareholders, an all-cash acquisition is the most complete form of liquidity a program can produce. There is no equity to hold through a lockup, no milestone schedule to chase, and no royalty to collect over a decade. The value is settled at closing.
Not every asset should be sold outright, and not every owner should want to. A license or co-development partnership keeps the company in the game and can be the right structure when the platform has more to give. But when a buyer is ready to own the asset and pay cash for it, that option belongs on the table, and it belongs there early, while the owner still has the leverage to choose.
The through-line across every one of these deals is the same. Certainty has a price, and buyers pay it for assets that are clean and de-risked. The work we do with the owners we represent is to build that certainty, and then to run a process that lets the market decide which structure, a sale, a license, or a co-development, pays the most for it.
Nothing here is investment advice, and this note is not an endorsement of any transaction described. Figures are as publicly reported.
Filling a pipeline gap?
Talk to us →Have a program worth de-risking?
See how we work with inventors →